orforglipron semaglutide HUGE news in the GLP-1 space! has outperformed oral in the ACHIEVE-3 clinical trial in patients with type 2 diabetes. Comment your thoughts below! ⬇️ Lilly claims its oral GLP-1

Barbot M, Zilio M, Scaroni C

We show that healthy subjects have stable NAD and glutathione concentrations and their ratios across different age groups, from 18 to 70 years

In the first trial, lixisenatide 20 g QD (n = 46) and liraglutide 1.2 (n = 44) and 1.8 mg QD (n = 46) were compared following 8 weeks treatment in 142 subjects with T2DM not adequately controlled with insulin glargine with or without metformin [17]

By mimicking this hormone, oral semaglutide reduces hunger and food cravings, helping you feel fuller on smaller portions

Surface immunoglobulin light chain expression in pre-B cell leukemias

It also protects implants